TY - JOUR T1 - Antitumor Activity of 3-Indolylmethanamines 31B and PS121912 JF - Anticancer Research JO - Anticancer Res SP - 6001 LP - 6007 VL - 35 IS - 11 AU - MARGARET L. GUTHRIE AU - PREETPAL S. SIDHU AU - EMILY K. HILL AU - TIMOTHY C. HORAN AU - PREMCHENDAR NANDHIKONDA AU - KELLY A. TESKE AU - NINA Y. YUAN AU - MARINA SIDORKO AU - REVATHI RODALI AU - JAMES M. COOK AU - LANLAN HAN AU - NICHOLAS R. SILVAGGI AU - DANIEL D. BIKLE AU - RICHARD G. MOORE AU - RAKESH K. SINGH AU - LEGGY A. ARNOLD Y1 - 2015/11/01 UR - http://ar.iiarjournals.org/content/35/11/6001.abstract N2 - Aim: To investigate the in vivo effects of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively. Materials and Methods: Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and western blotting were applied to demonstrate the induction of apoptosis. Xenografted mice were investigated to show the antitumor effects of 3-indolylmethanamines. 13C-Nuclear magnetic resource (NMR) and western blotting were used to demonstrate inhibition of glucose metabolism. Results: 31B inhibited ovarian cancer cell proliferation and activated caspase-3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and phosphorylated mitogen-activated protein kinases (MAPK), JUN N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38. 31B reduced ovarian cancer xenograft tumor growth and PS121912 inhibited the growth of HL-60-derived xenografts without any sign of toxicity. Compound 31B inhibited de novo glycolysis and lipogenesis mediated by the reduction of fatty acid synthase and lactate dehydrogenase-A expression. Conclusion: 3-Indolylmethanamines represent a new class of antitumor agents. We have shown for the first time the in vivo anticancer effects of 3-indolylmethanamines 31B and PS121912. ER -